Background. Although third-generation cephalosporins, such as ceftriaxone (CTRX), and pneumococcal fluoroquinolones, such as moxifloxacin (MXF), are currently recommended first-line antibiotics for empirical treatment of inpatients with community-acquired pneumonia, CTRX and MXF have never undergone a head-to-head comparison. We therefore compared the efficacy, safety, and speed and quality of defervescence of sequential intravenous or oral MXF and high-dose CTRX with or without erythromycin ( ) for patients with community-CTRX ‫ע‬ ERY acquired pneumonia requiring parenteral therapy.
. Design of the study in which moxifloxacin was compared with ceftriaxone with or without erythromycin for treatment of hospitalized patients with community-acquired pneumonia. iv, intravenous.
patients admitted to the hospital with community-acquired pneumonia who were receiving Medicare showed an unexpectedly lower mortality associated with receipt of cephalosporin-macrolide combination therapy or fluoroquinolone monotherapy, compared with b-lactam monotherapy or combination therapy with aminoglycosides. Furthermore, a prospective, controlled clinical trial demonstrated a higher clinical and microbiological efficacy for treatment with the fluoroquinolone moxifloxacin (MXF) than for treatment with amoxicillin-clavulanic acid with or without clarithromycin [8] . As a consequence of these studies, many ensuing practice guidelines now recommend third-generation cephalosporins combined with a macrolide or monotherapy combined with an antipneumococcal fluoroquinolone for treatment outside of intensive care units [5, [9] [10] [11] .
As more European countries adopt plans to reimburse hospitals for patient care on the basis of diagnosis-related categories, there is an increased interest in the speed of clinical improvement. A fast clinical improvement is the objective in switching from intravenous to oral medication for patients with community-acquired pneumonia, to reduce health care costs. One previous study used the Acute MOS 36-Item Short-Form Health Survey to compare the quality of life for patients who received MXF with the quality of life for patients who received a comparator drug and found no difference [12] . We therefore compared the efficacy, safety, and speed and quality of defervescence of the recommended first-line antibiotic therapy for treatment of community-acquired pneumonia, with special emphasis on the time course of clinical improvement, as assessed by laboratory testing and review of patient diary entries.
PATIENTS, MATERIALS, AND METHODS

Population.
The study cohort consisted of hospital-admitted patients aged у18 years who received a diagnosis of community-acquired pneumonia (as defined by the American Thoracic Society [3] ) and required initial parenteral treatment. Patients were required to have fever (defined as an axillary, oral, or cutaneous temperature of 138ЊC or a tympanic or rectal temperature of 138.5ЊC), leukocytosis (leukocyte level, 110,000 leukocytes/mL) or leukopenia (leukocyte level, !4500 leukocytes/mL), and/or у15% immature neutrophils; radiological evidence of an infiltrate consistent with pneumonia; and at least 2 of the following conditions: cough, dyspnea or tachypnea, rigor and/or chills, pleuritic chest pain, purulent sputum or changes in the characteristics of sputum, and auscultatory findings. Exclusion criteria included hospitalization for 15 days, suspected aspiration, need for mechanical ventilation, radiographically determined progression of disease, or evidence of severe sepsis; AIDS; pregnancy or breast-feeding; and known hypersensitivity to fluoroquinolone, b-lactam, or macrolide therapy.
Setting and design. This prospective, multicenter, multinational, randomized, open-label, comparative study was conducted from December 2001 through March 2003 at 54 centers in Germany, France, Greece, Lithuania, and Poland. Randomization was performed locally on the basis of a centrally generated randomization code. Written informed consent was obtained from all patients, and the protocol was approved by independent ethics committees or institutional review boards in all participating centers or countries.
Treatments. The assignment of patients to the treatment groups is summarized in figure 1 . In one group, 400 mg of MXF was administered intravenously once daily during a 60-min period. The switch to orally administered MXF could be made at the discretion of the investigator, provided that the patient's clinical condition had improved, the patient was able to tolerate oral medication, and there was no evidence of markedly reduced gastrointestinal motility and/or absorption.
In the other group, 2 g of ceftriaxone with or without erythromycin ( ) was administered intravenously once CTRX ‫ע‬ ERY daily during an interval of at least 30 min. In cases of proven or suspected infection with an atypical pathogen, 1 g of ERY administered intravenously every 6-8 h could be given concomitantly by means of a 60-min infusion.
Patients were to be treated for 7-14 days. Use of additional antimicrobial therapy was not permitted.
Evaluations. In addition to undergoing a pretreatment enrollment evaluation, participants were assessed at the following times: during treatment (3-5 days after receipt of the first dose of study therapy), at the end of treatment (7-14 days after first dose), and at the test-of-cure visit (5-20 days after receipt of the final dose). Although the interval during which the testof-cure assessment was to be performed was originally defined in the protocol as 7-14 days after receipt of the final dose, at the data validation meeting, it was extended to 5-20 days after completion of therapy.
Pneumonia severity index scores were determined a posteriori on the basis of the criteria of Fine et al. [13] , and not all characteristics were initially recorded. For variables that were not available, no points were added to the total score. For glucose level, 10 points were added to the score if diabetes mellitus was reported in the medical history. Patients graded the following signs and symptoms in a diary during the study: dyspnea, cough, chest pain, and quality, quantity, and color of sputum. Signs and symptoms were analyzed on the basis of the following categories: chest pain, graded as absent, frequent, or always; dyspnea, graded as absent, during speech, or during rest; cough, graded as absent, severe, or very severe; weakness, fatigue, and fainting, graded as absent, moderate, or severe; color of sputum, graded as absent, yellowish green, or brownish and bloody; and quantity of sputum, graded as absent, 1 tablespoon, one-half glass, or more than one-half glass.
Criteria of evaluation. The primary efficacy variable was the clinical response at the test-of-cure visit 5-20 days after receipt of the final dose of the study drug. Secondary efficacy variables were clinical response 3-5 days after starting treatment and at the end of treatment, bacteriological response at the testof-cure visit and at the end of treatment, and clinical and bacteriological response at the test-of-cure visit for patients with proven bacterial pneumonia.
Patients in the validated per-protocol population had to have a diagnosis of pneumonia confirmed on an outpatient basis or within 5 days after hospital admission and no other systemic antimicrobial agent administered concomitantly with the study drug, unless treatment failure occurred. Further requirements for inclusion in the validated per-protocol analysis were receipt of study drug(s) for a minimum of 48 h (in cases of clinical failure) or for 5 full days (in cases of clinical cure), documented compliance with у80% of the regimen of study therapy, no protocol violations that influenced treatment efficacy, and no missing or indeterminate data. The intention-to-treat analysis included all randomized patients who had received at least 1 dose of study drug.
Definitions of clinical response. Clinical improvement 3-5 days after starting treatment was defined as marked or moderate reduction in the severity and/or number of signs and symptoms of infection. Resolution at the end-of-treatment was defined as resolution or improvement of clinical signs and symptoms related to the infection that did not require further antibiotic therapy. Clinical failure 3-5 days after starting treatment or at the end of treatment was defined as failure to respond or insufficient response to the study drug treatment that required a modification of antibacterial therapy. Continued resolution at the test-of-cure visit was defined as resolution or improvement of clinical signs and symptoms related to the infection that did not require any antibiotic therapy. Relapse at the test-of-cure visit was defined as reappearance of the signs and symptoms of infection that required further antimicrobial therapy. Indeterminate clinical response was defined as a clinical assessment that could not be determined. Safety assessment included surveillance for treatment-emergent adverse events and outcome, abnormal laboratory findings, and changes in vital signs.
Statistical analyses. The study was designed to test whether, at the test-of-cure visit, MXF was at least as effective as for treatment of community-acquired pneu-CTRX ‫ע‬ ERY monia in clinically evaluable patients. For the primary efficacy variable, a 2-sided 95% CI for the true difference of the 2 clinical success rates (the success rate for MXF minus the success rate for , where clinical success was defined as "clinical CTRX ‫ע‬ ERY cure") was determined by use of Mantel-Haenszel weights calculated with respect to regions (individual study centers were pooled into 4 regions: northern Germany, southern Germany, France and Greece, and Poland and Lithuania). If the lower limit of this 95% CI was greater than Ϫ15%, MXF was considered to be clinically at least as effective as for CTRX ‫ע‬ ERY treatment of community-acquired pneumonia. The secondary efficacy variables were analyzed exploratively.
A combined analysis of end-of-treatment and test-of-cure data was performed. All data on clinical failures at the end-oftreatment visit were carried forward. All statistical tests were 2-sided and performed at a significance level of .05. Valid-perprotocol analysis was the primary efficacy analysis, whereas the intention-to-treat analysis was supportive. The sample size of 139 evaluable patients per group was based on an a of 5%, a b of 10%, an equivalence D of 15%, a 10% adjustment for the multicenter design, and an assumed success rate of 85% in both groups. Comparability of treatment groups was established by the Cochran-Mantel-Haenszel test stratified by region (for dis- 
RESULTS
Patient characteristics at baseline. All 397 patients received at least 1 dose of study drug and were included in the intentionto-treat population. A total of 80 patients (20.2%) had to be excluded from the validated per-protocol analysis, mostly because essential data were missing or invalid (14.9%), the time schedule was violated (14.4%), inclusion criteria were absent and/or exclusion criteria were present (4.5%), or the duration of therapy was insufficient (3.8%). A patient could have 11 reason for exclusion. The remaining 317 patients (79.8%, of whom 161 received MXF and 156 received ) were CTRX ‫ע‬ ERY eligible for the efficacy analysis. The percentage of patients with valid microbiological findings was too small for performance of a meaningful analysis. Overall, 13 patients (4.1%) in the validated per-protocol population had already been hospitalized before the diagnosis of pneumonia, but only 1 (a patient in the MXF group) had been hospitalized for 13 days. Both treatment groups were well matched with respect to baseline and disease-specific characteristics, including pneumonia severity index scores, as summarized in table 1.
Course and duration of study therapy. Of 161 patients in the validated per-protocol population who were treated with MXF, 130 (80.7%) had therapy switched to oral MXF after a mean duration of 5.7 days (median duration, 5 days). The remaining 31 patients (19.3%) received intravenous MXF during the entire treatment period. Of 156 patients in the validated per-protocol population who received , 59 CTRX ‫ע‬ ERY (37.8%) were treated with CTRX and ERY concomitantly.
The mean duration of intravenous treatment was 5.4 days (median duration, 5 days) for patients who received MXF and 9.5 days (median duration, 10 days) for patients who received . Patients whose treatment was switched to an CTRX ‫ע‬ ERY oral formulation took MXF tablets for a mean duration of 5.9 days. The mean duration of total study drug treatment was 10.1 days (median duration, 10 days) for patients who received ). Table 2 summarizes the results of the analysis P 1 .1 of efficacy at the end of treatment and the test of cure for the validated per-protocol population and the intention-to-treat populations. Because the 95% CI is greater than Ϫ10%, the equivalence in clinical outcome between the 2 regimens is proven.
Only 4 patients in the MXF group and 3 patients in the group who were judged as cured at the end-of-CTRX ‫ע‬ ERY treatment visit were considered to have had clinical recurrence or relapse of community-acquired pneumonia at the test-ofcure visit. One MXF-treated patient, who was not assessed at the end of treatment, had achieved clinical resolution at the test-of-cure visit.
In subgroups of patients matched for age, sex, and pneumonia severity index score, the clinical cure rates at the testof-cure visit were not significantly different in both treatment groups (data not shown ). P p .326
At baseline, the mean body temperature was 38.4ЊC for both treatment groups in the validated per-protocol population (table 1). Among patients with fever at study entry, sustained defervescence occurred significantly earlier in the MXF group, compared with the group (median onset, 3.0 vs. CTRX ‫ע‬ ERY 4.0 days after treatment initiation) (figure 2). The difference between treatment groups was statistically significant in the validated per-protocol population ( , by the Wilcoxon P ! .003 rank-sum test stratified by region), as well as in the intentionto-treat population ( ). P ! .019 Pretreatment C-reactive protein levels were determined for 312 patients (all of whom were in the validated per-protocol population). Although the mean value at baseline was higher in the MXF group, the absolute decrease was larger than that in the group at all assessed times during therapy CTRX ‫ע‬ ERY and was equivalent to that in the group at the CTRX ‫ע‬ ERY end-of-treatment and test-of-cure visits.
Patient diary. The time course of clinical improvement was assessed by review of patient diary entries. During the first days of therapy, MXF-treated patients reported a consistently faster improvement of signs and symptoms specific to communityacquired pneumonia, such as chest pain, weakness, and sputum color, compared with -treated patients (figure 3). CTRX ‫ע‬ ERY There was no definite difference between the treatment groups with regard to the course of improvement of cough, dyspnea, and sputum quantity. Patients treated with MXF also reported feeling better after a median of 3 days of treatment, compared with a median of 4 days of treatment for patients treated with . CTRX ‫ע‬ ERY Duration of hospitalization. The median duration of hospitalization (all wards) was 9 days for patients treated with MXF and 11 days for those treated with (mean du-CTRX ‫ע‬ ERY ration, 9.8 and 11.1 days, respectively;
). P ! .001 Tolerability and safety. All 397 patients were eligible for safety analysis. A total of 65 patients (16.4%) discontinued study therapy (primarily because of insufficient therapeutic effect [5.0% of patients] and occurrence of adverse events [4.8% of patients]), with no statistically significant difference between treatment groups. Table 3 summarizes the incidence of treatment-emergent adverse events and the most common clinical and laboratory drug-related adverse events that occurred after the first dose of study drug, up to 14 days after the end of treatment. There was no relevant difference between treatment groups in the incidences for these variables. The vast majority of adverse events were mild to moderate. At the test-of-cure visit, most adverse events and serious adverse events had resolved. Discontinuation of therapy primarily because of an adverse event occurred for 10 patients (5%) in the MXF group and 9 patients (4.6%) in the group. No case of CTRX ‫ע‬ ERY relevant QT prolongation was observed. None of the 13 deaths reported in this study had a causal relationship with the study medications.
DISCUSSION
This study demonstrated that the efficacy of intravenous or (for some patients) oral sequential monotherapy with MXF is clinically equivalent to the efficacy of intravenous, high-dose for the treatment of community-acquired pneu-CTRX ‫ע‬ ERY monia in hospitalized patients. This equivalence was observed in all subgroups of patients, independent of age, sex, and disease severity.
Clinical improvement was evaluated on the basis of objective criteria (e.g., fever and C-reactive protein level) and subjective criteria (reported in patient diary entries). Treatment with MXF was associated with clinical improvement that was faster than that of treatment with , the standard regimen CTRX ‫ע‬ ERY used against community-acquired pneumonia. Time to resolution of fever was significantly shorter in the MXF group, compared with the group. The more rapid onset CTRX ‫ע‬ ERY of treatment effect was also reflected in the patient diary entries, showing a faster resolution of signs and symptoms associated with community-acquired pneumonia, such as chest pain, weakness, and sputum color. Few studies have investigated the time course of response to therapy [12, 14] . In our study, daily documentation of signs and symptoms, as summarized in patient diary entries, was used. The practicability of this instrument has been demonstrated in previous studies [15, 16] .
Compared with the regimen, the MXF regi-CTRX ‫ע‬ ERY men shortened the duration of hospitalization by a median of 2 days and a mean of 1.3 days in the validated per-protocol population. Marrie et al. [17] and Castro-Guardiola et al. [18] demonstrated that, for patients who are able to eat and have achieved clinical improvement, a switch from intravenous to oral therapy is safe and efficacious. In addition to an early switch to oral drugs, a decrease in the duration of antibiotic treatment could reduce the duration of hospital stay, which is the most important cost factor in the management of community-acquired pneumonia [19] .
The duration of antibiotic therapy for patients with community-acquired pneumonia is recommended to be 7-10 days or longer [5, 10] . In a study of community-acquired pneumonia caused by atypical pathogens, 5-day therapy with a new fluoroquinolone was as effective as 10-day therapy [20] . The fast resolution of clinical symptoms and biochemical markers in our study supports the hypothesis that, for patients with mild to moderate disease, short-term treatment could be a feasible and safe therapy option.
Although high efficacy has been demonstrated for both regimens, the clinical cure rate in this study was lower than that in other controlled clinical studies, such as the TARGET trial [8] . However, the rate of clinical failure for both regimens in the intention-to-treat population (12.5% in the MXF group vs. 11.7% in the group) was well below the mean CTRX ‫ע‬ ERY failure rate of 16% found in a recent meta-analysis of 16 clinical , ceftriaxone with or without erythromycin. CTRX ‫ע‬ ERY trials involving patients with community-acquired pneumonia [21] . The CTRX group was not analyzed separately with respect to the addition of the macrolide, because such an analysis may have had an inclusion bias (i.e., the more severe the illness was at baseline, the higher the probability that the macrolide was concomitantly administered). This resulted in a higher mortality associated with therapy (8% [6 of 59 pa-CTRX ‫ע‬ ERY tients]) than with CTRX therapy alone (0.8% [1 of 97 patients]) in our study. Because of the post hoc nature of this comparison, we would refrain from further interpretation of this finding. There are some possible limitations of the study that deserve consideration. First, a large number of study patients had a class I-III pneumonia severity score, and the need for hospitalization of these patients is a matter of debate. All current guidelines emphasize the importance of the clinical judgment regarding the decision to hospitalize. In one Canadian study, almost 50% of the patients with community-acquired pneumonia with a severity index score of I-III were also treated in the hospital [17] , because it is known that the score may underestimate the severity of pneumonia for younger patients. In addition, the applicability of most prognostic scoring systems to the care of older patients has been questioned recently [22] . In our study, ∼86% of the patients had at least 1 prognostically relevant comorbidity. Because some clinical information included in the original pneumonia severity index score was not recorded in the patient charts, there was probably a systematic, although small, underestimation of the score. The low proportion of patients with a high risk for morbidity and mortality corresponding to severity classes IV and V is, more importantly, a consequence of the exclusion of patients with pneumonia requiring mechanical ventilation.
Second, no strict criteria for hospital discharge were defined, and data associated with this issue have to be interpreted with caution. Third, the MXF group could be switched to oral therapy, whereas the group could not. The intra-CTRX ‫ע‬ ERY venous administration of CTRX during the entire treatment reflects current clinical practice in many clinics. Nevertheless, the emphasis of this study was on the comparison of the clinical efficacy and safety of the treatments and the speed and quality of defervescence.
Finally, analysis of the time to onset of symptoms initially also included patients who formally fulfilled criteria of nosocomial pneumonia. Because the focus of the study was on community-acquired pneumonia, only 1 (0.3%) of 317 patients whose symptoms began 172 h after presentation to the hospital was finally included.
In conclusion, among adult patients hospitalized with community-acquired pneumonia, sequential intravenous or (for some patients) oral MXF therapy was clinically equivalent to high-dose therapy, with the additional benefit CTRX ‫ע‬ ERY of faster symptom relief, as recorded in patient diary entries. Monotherapy with MXF is an adequate treatment option for patients hospitalized with community-acquired pneumonia.
